20:32:43 EST Thu 19 Nov 2026
Enter Symbol
or Name
USA
CA



ASEP Medical Holdings Inc (2)
Symbol ASEP
Shares Issued 11,127,327
Close 2026-11-19 C$ 0.10
Market Cap C$ 1,112,733
Recent Sedar+ Documents

Asep Medical extends LIFE offering

2026-11-19 19:09 ET - News Release

Subject: For immediate release / Asep Medical Holdings Inc. Word Document

File: '\\swfile\EmailIn\20261119 155343 Attachment Asep - PR re Extension LIFE Offering(34495261.1).docx'

Asep Medical Holdings Inc.

1

FOR IMMEDIATE RELEASE

Asep Medical Announces Extension of LIFE Offering Closing Date

VANCOUVER, BC, November 19, 2026 - Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB:SEPSF) (FSE: JJ8) is pleased to announce that it has received approval from the Canadian Securities Exchange (the "CSE") to extend the closing date of its previously announced non-brokered private placement financing under the Listed Issuer Financing Exemption (the "LIFE Offering") to January 3, 2027.

The extension has been granted to allow the Company additional time to complete the LIFE Offering. All other terms of the LIFE Offering remain unchanged, as previously disclosed in the Company's news release dated October 9, 2026 and the related offering document.

The LIFE Offering consists of up to 9,000,000 units of the Company (each, a "Unit") at a price of $0.10 per Unit for maximum gross proceeds of $900,000. Each Unit consists of one common share in the capital of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant entitles the holder to acquire one additional Common Share at an exercise price of $0.12 per Common Share for a period of 24 months following closing.

The LIFE Offering is being completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions. The securities issued pursuant to the LIFE Offering are expected to be immediately freely tradeable under applicable Canadian securities legislation.

The Company intends to use the available funds from the LIFE Offering, together with its existing additional sources of funding, primarily for the identification and evaluation of companies and technologies for potential acquisition and integration into the Company's business, repayment of existing debts and general working capital purposes.

The amended offering document related to the LIFE Offering can be accessed under the Company's profile on SEDAR+ and on the Company's website. Prospective investors should read the offering document before making an investment decision.

Completion of the LIFE Offering remains subject to the final approval of the CSE.

ABOUT ASEP MEDICAL HOLDINGS INC.

Asep Medical is an investment issuer focused on investing into biotechnology research and development assets and is based in Victoria, BC, Canada. The Company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E. W. Hancock, one of the world's foremost microbiologists. Asep holds a significant interest in two private companies - Sepset Biosciences (Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the Company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors.

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

FOR MORE INFORMATION, PLEASE CONTACT

Chris Dallin, Marketing Director ASEP Medical Holdings Inc.

E. chris@asepmedical.com

T. +1 (604) 362-3654

FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plans," "continues," "expects," "projects," "intends," "believes," "estimates," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements include, but are not limited to, the completion and timing of the LIFE Offering, the issuance of the Units, Common Shares and Warrants, the intended use of available funds, and the receipt of approval of the Canadian Securities Exchange, the successful execution of the Company's business plan, the development, testing, and commercialization of its sepsis diagnostic test (Sepset), and other statements regarding the Company's proposed business plans and technologies. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks, including the risk that the Company's products may not perform as expected, may not receive regulatory approvals, or may not generate revenue as anticipated. Additional risk actors are identified in the Asep Medical Holdings Inc. prospectus dated November 9, 2021, and in the Company's management discussion and analysis, available for review under the Company's profile at www.sedarplus.ca. Asep Medical Holdings Inc. undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

© 2026 Canjex Publishing Ltd. All rights reserved.